Press Releases

Here is an up-to-date collection of any information given to the press. It’s a big collection, so try not to look at it all in one sitting.

Press Releases

 
Press Releases
Date Title and Summary View
Mar 1, 2018 BOSTON, March 01, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation ...
PDF
Feb 13, 2018 BOSTON, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that management will host a conference call and webcast slide presentation on Thursday, March 1, at 4:30 p.m. ET to provide a corporate update and discuss financial results for the fourth quarter and year ended Dec. 31, 2017.  ...
PDF
Feb 12, 2018 BOSTON, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of...
PDF
Feb 6, 2018 BOSTON, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today responded to unfounded rumors regarding possible financing plans of the Company. Management states that it knows of no developments at the Company that would be the cause of the recent volatility and decline in the stock price. ...
PDF
Jan 9, 2018 - Controlled IL-12 advancing as drug platform as monotherapy and in combination with OPDIVO® (nivolumab) -- Non-viral T-cell platform shows potential for efficacy, scalability and cost reduction for multiple oncology targets - BOSTON, Jan. 09, 2018 (GLOBE NEWSWIRE...
PDF
Dec 21, 2017 BOSTON, Dec. 21, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 10 a.m. PST. The presentation will include...
PDF
Dec 10, 2017 — Clinical data show continued survival benefit, tumor response, and multi-year persistence of Sleeping Beauty-modified CD19-specific CAR+ T cells —— Point-of-care CD19-specific CAR+ T cells co-expressing mbIL15 with control switch show ...
PDF
Nov 20, 2017 — Controlled IL-12 gene therapy turns cold tumors hot —— MRI indicates decreasing size of brain tumor lesions in several patients —— Median overall survival for patients with recurrent glioblastoma (rGBM) maintained at 12.5 months in 20mg cohort with longer...
PDF
Nov 17, 2017 BOSTON, Nov. 17, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company developing new gene and cell-based immunotherapies for cancer, today announced that it will host a conference call and webcast slide presentation on Monday, November 20, 2017 at 10:15 a.m. ET to discuss updated clinica...
PDF
Nov 10, 2017 BOSTON, Nov. 10, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that David Mauney, M.D., CBO and interim COO, will present at the Stifel 2017 Healthcare Conference in New York on Tuesday, November 14, 2017 at 11:00 a.m. ET. To access a live audio webcast of the pre...
PDF
Page:
1
... NextLast